Delivering quality therapy since 1901

Press releases

 

 

European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia1092<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.00000000000<p>​Gedeon Richter Plc. (&quot;Richter&quot;) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the company's application for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. The marketing authorization application has been submitted to EMA in March 2016. Subject to approval by the European Commission, Richter is expected to receive in two months a marketing authorization for cariprazine valid for all European Union Member States.</p>2017-05-18T22:00:00Z5/19/2017 12:22:14 PM1747http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter and DM Bio agreement on technology transfer and license-in of biosimilar Trastuzumab1920<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​Gedeon Richter Plc. (&quot;Richter&quot;) today announces that it has signed a technology transfer and license-in agreement with DM Bio (&quot;DM Bio&quot;) in respect of the development and commercialization of DM Bio's biosimilar monoclonal antibody, Trastuzumab.</p>2016-10-18T22:00:00Z10/21/2016 12:18:33 PM2597http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter and Allergan Provide Update on Cariprazine Program1663<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​</p><p style="text-align&#58;justify;"><strong>BUDAPEST, Hungary</strong> and <strong>DUBLIN, Ireland</strong> –&#160;Allergan plc&#160;(NYSE&#58; AGN), a leading global pharmaceutical company and Gedeon Richter Plc., today provided a clinical and regulatory update on cariprazine. For more than a decade both companies have conducted&#160; over 20 clinical trials enrolling thousands of patients worldwide to evaluate the&#160; efficacy and safety of cariprazine for patients suffering from a broad range of mental health illnesses.&#160; </p><p style="text-align&#58;justify;">&#160;</p>2016-08-04T22:00:00Z8/5/2016 5:55:36 AM1431http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter announces the acquisition of Finox Holding for a consideration of CHF190 million675<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.000000000002016-06-29T22:00:00Z6/30/2016 8:44:52 AM3022http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids1318<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​DUBLIN, Ireland and BUDAPEST, Hungary – 9 May 2016, --&#160;Allergan Plc (NYSE&#58; AGN) and Gedeon Richter Plc. today announced positive results from Venus I, one of two pivotal Phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with uterine fibroids. </p>2016-05-08T22:00:00Z5/9/2016 6:37:46 AM1133http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
EMA started the evaluation of Richter’s marketing authorisation application for cariprazine for the treatment of schizophrenia1178<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​Gedeon Richter Plc. (&quot;Richter&quot;) today announced that the European Medicines Agency (EMA) has accepted Richter's regulatory submission for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. Cariprazine was discovered by Richter scientists and is licensed to Allergan (earlier Forest / Actavis), in the U.S. and Canada. Following its FDA approval in September 2015, the product has been recently launched in the USA under the trademark of VRAYLAR<sup>TM</sup> for the treatment of both schizophrenia and bipolar mania. </p>2016-03-28T22:00:00Z3/29/2016 5:51:47 AM2242http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Gedeon Richter Plc to further expand its biotechnology plant in Debrecen, which has a cutting edge technology, unique in the region655<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​<strong>Gedeon Richter Plc. will spend HUF 15 billion on an investment project to expand its biotechnology plant founded in 2012 to develop and manufacture biosimilar products, which has a unique, cutting edge technology in the region. The planned investment will help the Company create another 125 jobs for highly qualified experts. The plant in Debrecen will be manufacturing products with high intellectual added value that make it possible to provide the most advanced treatment while at the same time ensuring significant savings for the national health insurance fund. These products represent a significant value for both the patients and the national economy and also contribute to further expanding Richter's export potential. </strong></p>2016-03-09T23:00:00Z3/10/2016 1:38:26 PM985http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter wins prestigious award648<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​<strong>Gedeon Richter Plc's social responsibility efforts have been recognised with the Global CSR Excellence and Leadership Award.</strong></p>2016-02-18T23:00:00Z2/19/2016 11:29:11 AM742http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
Richter further strengthens its presence in China1129<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​</p><p style="text-align&#58;justify;">Gedeon Richter Plc. (&quot;Richter&quot;) announced today that it acquired from its partner, Rxmidas Pharmaceuticals Holdings Ltd. its outstanding 50% stake in Gedeon Richter Rxmidas Joint Venture Co. Ltd. following the setting up of a joint venture with an initial 50% share of equity announced in December 2010. Subsequent to the present acquisition, Richter now holds 100% of Gedeon Richter Rxmidas Joint Venture Co. Ltd., consequently will be in full charge of its contraceptive and OTC business in China. The financial terms of the agreement are undisclosed. </p><p style="text-align&#58;justify;">&#160;</p>2016-01-21T23:00:00Z1/22/2016 7:02:46 AM1334http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx
EMA started the evaluation of Richter’s marketing authorisation application for biosimilar teriparatide177<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2016.00000000000<p>​<strong>Budapest,</strong> <strong>4 January 2016</strong> – Gedeon Richter Plc. (&quot;Richter&quot;) today announced that the European Medicines Agency (EMA) has accepted Richter's regulatory submission for the proposed biosimilar to Eli Lilly's Forteo (teriparatide). </p>2016-01-03T23:00:00Z1/4/2016 1:51:17 PM3362http://rgextend.richter.hu/en-US/pressroom/press-release/Pages/press-releaseshtmlFalseaspx